Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 + Pemetrexed + Carboplatin in EGFR-mutant NSCLC (HARMONi)
NCT06396065Phase 3Active, not recruiting
- Sponsor
- Summit Therapeutics
- Start
- May 2023
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of ivonescimab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Summit Therapeutics. Started May 2023; status: active, not recruiting.
02
Drugs
ivonescimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT06396065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06396065.